A cyberattack forces a guidance cut — the stock falls on timing and disruption, not on demand or product risk. Historically, quality medical-device names tend to recover once operations are restored and the market realizes the shortfall was pushed into ne

Verdict: a coherent recovery thesis, but the entry never fires — stay on watch

The recovery-swing case for BSX has real substance: revenue grew 19.9% to $20.1B in fiscal 2025 with a 99th-percentile free cash flow among Health Care peers, and for the June 2026 quarter free cash flow rebounded to $1.28B from $171M while gross margin improved to 70.7%. The strongest filed signal for the thesis is insider behavior — for the six months ended June 30, 2026, BSX insiders were net open-market buyers of roughly $10.0M across seven holders, the only net buyer among the three tickers (versus net selling of about $46.7M at ABT), though that ownership data reflects the period that has already closed, not the current cycle. Against this, the company itself says it is unlikely to meet its 2026 sales and profit forecast after the cyberattack (per Barron's and Yahoo Finance, September 8, 2026), and net margin compressed to 16.6% from 25.7% quarter over quarter — the damage may be more than timing. The setup is also strictly a wait: RSI must first dip to 35 or below and reclaim, ADX (now 67.0) must fall below 25, and price must clear the $48.66 EMA — conditions that never fired in 1,234 daily bars over five years, and parameter-sensitivity work returned no recommended alternative setup. The verdict is to watch, with the September-quarter cash flow report and the mid-September ownership filings as the next fundamental gates. A sustained close below $46.00 would take the recovery-rebound read off the table.

Trade now: BSX recovery entry is armed but not triggered

## Trade now **BSX last close: $47.80 — the entry is not triggered. Wait.** This idea is a recovery-swing watch on BSX: the thesis argues the cyberattack-driven guidance cut is a timing event, not a demand event, so a pullback with momentum turning back up becomes the entry. The strategy trades BSX daily bars and requires four things at once, and right now only one is in place: - **Bollinger lower band below 50 — met** (currently 49.77). - **RSI (14) crossing above 35 — not met.** RSI is 43.0 now, 8.0 points above the trigger; the entry needs RSI to first dip to or below 35 and then cross back above it. - **Price above the 20-day EMA — near but not met.** Price is $47.80 vs the EMA at $48.66, about $0.86 below. - **ADX (14) below 25 — far.** ADX is 67.0, roughly 42 points above the threshold; trend strength needs to cool considerably. "Wait" means: no position until all four conditions line up on the same daily bar. If an entry triggers, the risk framework is explicit — a hard stop at -2.4% from entry (roughly $46.65 from a $47.80-style entry, also capped by a close crossing below the second support level at $46.00) and a take-profit at +4.8% (about $50.09, with the first resistance level at $48.00 acting as an earlier exit). That is a fixed 2-to-1 reward-to-risk per trade, sized at 2.4% account risk with a 25% maximum position. Given BSX's realized swings — a 60.6% maximum drawdown over the last two years and a 37.4% annualized EWMA volatility — respecting that stop is not optional. One calibration note: the research author authorized a bounded parameter search after the strict entry conditions produced no triggers across 1,234 evaluated daily bars, but the sensitivity evaluation exceeded its time budget, so **no robust alternative setup was established** — the published conditions above remain the live ones.

A Demand Story Interrupted by an IT Incident, Not a Broken Business

The thesis rests on a distinction the numbers support: Boston Scientific's sales and profit forecast for 2026 is now at risk because of a cyberattack, per the Barron's and Yahoo Finance reports of September 8, 2026 — an operational disruption, not a demand or product failure. Nothing in the fundamentals suggests eroding end-market appetite. Through fiscal 2025, Boston Scientific grew revenue 19.9% year over year to $20.1B, with a 69.0% gross margin and $3.66B in free cash flow — placing it in the 99th percentile of Health Care peers on free cash flow and the 60th percentile on revenue growth. That is a company whose core business was compounding, not one being rescued by an event. The most recent quarterly print reinforces the point rather than undermining it. For the quarter ended June 30, 2026, revenue rose 4.6% sequentially to $5.44B, gross margin improved to 70.7% from 69.5%, and free cash flow rebounded to $1.28B from just $171M in the March quarter — a swing of roughly $1.1B in a single quarter. Margins at the operating line also held, at 21.6% versus 21.2%. The trajectory into the disruption was improving on nearly every line a value investor would check. Ownership posture lines up with the recovery thesis too. For the six months ended June 30, 2026, institutional filers show net open-market insider buying of about $10.0M across seven holders — the only one of the three suggested tickers with net buying, against net selling of roughly $46.7M at Abbott and about $0.6M at Medtronic. Insiders committing their own money while the news flow deteriorates is exactly the behavior you expect if management reads the guidance cut as timing rather than loss. The strategy profile matches the setup: a long entry on Boston Scientific daily bars that waits for a pullback to volatility-band support with momentum turning back up and trend strength low. To be precise about the evidence: the entry conditions did not occur on any of the 1,234 evaluated daily bars in the past 60 months, nor over the 24- and 12-month windows, so this is a watch-list setup rather than an active…

Scores

• Conviction score breakdown: 44
• Thesis support: 65
• Trade readiness: 20
• Risk quality: 55
• Trigger proximity: 15
• Fundamentals trend: 65

Watch items

• BSX — RSI (14)
• BSX — ADX (14)
• BSX — Close vs 20-day EMA
• BSX — Close vs second support level
• BSX — Insider net open-market buying
• BSX — Free cash flow (next quarterly filing)
• BSX — Net margin (next quarterly filing)